Adaptive Biotechnologies reports Thursday with two signals — defensive options positioning and persistent insider selling — both intensifying rather than fading since yesterday's note.
The options market is the most acute data point right now. The put/call ratio has climbed further to 0.175, running more than three standard deviations above its 20-day average of 0.029. That average was itself suppressed by a long stretch of near-zero PCR readings throughout July, making the recent spike all the more pronounced. The stock has drifted slightly lower from yesterday's $22.52 to $22.56, essentially unchanged, but the demand for downside protection has continued to build.
The insider picture remains unchanged from yesterday's note: Harlan Robins's $18.5 million in sales across multiple July transactions, compounded by disposals from the Chief Commercial Officer and HR Director, puts the 90-day insider net at roughly $32.6 million sold. The stock is trading almost exactly at the prices where insiders have been exiting, which tells its own story about where sellers see fair value.
Short interest, by contrast, reads as a moderating signal rather than an amplifier. At 7.4% of the float — up 26.7% over the past month but down roughly 2% on the week — bears have built meaningful positions but appear to have steadied heading into the print. Borrow conditions are loose: availability runs near 580%, well clear of any squeeze risk, and the cost to borrow remains just under 0.5%. The ORTEX short score of 52.7 sits near the midpoint of its recent range, consistent with elevated but non-extreme short interest.
The Street offers limited resolution on valuation. The consensus mean price target of around $22 sits essentially at the current price, with Morgan Stanley neutral at $20 and buy-rated firms at Guggenheim, BTIG, and JP Morgan clustered in the $19–$22 range. Bulls point to clonoSEQ volume growth and the strategic separation of the MRD business as catalysts; bears flag the premium multiple — EV/EBITDA above 170 on an unprofitable base — and the inherent lumpiness of specialty lab revenues. The stock has traded through most of those buy targets already, leaving the bullish case dependent on a guidance raise rather than a re-rating.
The print will test whether a business that has already rallied 38% year-to-date can deliver revenue and volume numbers that justify staying long at prices its own insiders have used to reduce exposure.
See the live data behind this article on ORTEX.
Open ADPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
